Search for common genes
The common genes query provides a unique data-mining feature, which could be computed because of the homogenous
re-analysis of all the data that was performed in ParkDB.
Since we have incorporated information on orthology between genes the researcher can query the database for the
commons genes between two experiments even across experiments performed in different organisms

Select from list one

-- DANIO RERIO -- E-GEOD-13348 Foggy mutant zebrafish vs Wild Type (Elizabeth Salomon) -- HOMO SAPIENS -- E-GEOD-7307 Substantia Nigra pars compacta cDNA from Parkinson's patients VS Substantia Nigra pars compacta cDNA from healthy patients (Richard Roth) E-GEOD-20141 Substantia Nigra pars compacta cDNA from Parkinson's patients VS Substantia Nigra pars compacta cDNA from healthy patients (Frank Middleton) E-MEXP-1416 Substantia Nigra pars compacta cDNA from Parkinson's patients VS Substantia Nigra pars compacta cDNA from healthy patients (Ippolita Cantuti-Castelvetri) E-GEOD-8397 Set 1. Lateral Substantia Nigra cDNA from Parkinson's patients VS Lateral Substantia Nigra cDNA from healthy patients (Linda Moran) E-GEOD-8397 Set 1. Medial Substantia Nigra cDNA from Parkinson's patients VS Medial Substantia Nigra cDNA from healthy patients (Linda Moran) E-GEOD-8397 Set 1. Superior (Frontal Cortex) cDNA from Parkinson's patients VS Superior Substantia Nigra cDNA from healthy patients (Linda Moran) E-GEOD-8397 Set 2. Lateral Substantia Nigra cDNA from Parkinson's patients VS Lateral Substantia Nigra cDNA from healthy patients (Linda Moran) E-GEOD-8397 Set 2. Medial Substantia Nigra cDNA from Parkinson's patients VS Medial Substantia Nigra cDNA from healthy patients (Linda Moran) E-GEOD-8397 Set 2. Superior (Frontal Cortex) cDNA from Parkinson's patients VS Superior Substantia Nigra cDNA from healthy patients (Linda Moran) E-GEOD-7621 Substantia Nigra cDNA from Parkinson's patients VS Substantia compacta cDNA from healthy patients (Jarlath ffrench-Mullen) E-GEOD-20146 Globus Pallidus cDNA from Parkinson's patients VS Globus Pallidus cDNA from healthy patients (Frank Middleton) E-GEOD-20153 B lymphocytes transformed with EBV cDNA from Parkinson's patients VS B lymphocytes transformed with EBV cDNA from healthy patients (Frank Middleton) E-GEOD-6613 Total blood cDNA from Parkinson's patients VS Total blood cDNA from healthy patients (Aron Eklund) E-GEOD-20168 Prefrontal cortex area 9 cDNA from Parkinson's patients VS Prefrontal cortex area 9 cDNA from healthy patients (Frank Middleton) E-GEOD-14429 Human HEK293 cells treated with proteasome inhibitor epoxomicin vs untreated cells (Allen HK Chang) E-GEOD-4773 Cultured SK-N-MC neuroblastoma cells at 1 week during rotenone exposure vs untreated (Elizabeth Salomon) E-GEOD-4773 Cultured SK-N-MC neuroblastoma cells at 2 week during rotenone exposure vs untreated (Elizabeth Salomon) E-GEOD-4773 Cultured SK-N-MC neuroblastoma cells at 3 week during rotenone exposure vs untreated (Elizabeth Salomon) E-GEOD-3064 X linked dystonia parkinsonism patients vs control tissue (Gen Tamiya) E-GEOD-20333 Substantia Nigra from Parkinso's patients vs control (jasmine jacob ) E-GEOD-20295 Parkinson's disease multiple brain regions vs control (Frank Middleton) E-GEOD-20291 Parkinson's disease putament vs control (Frank Middleton) E-GEOD-20292 Parkinson's disease substantia nigra vs control (Frank Middleton) E-GEOD-17204 Human neuroblastoma cells stably transfected with RNAi against DJ-1 vs scramble (Paola Roncaglia) -- MUS MUSCULUS -- E-GEOD-13033 HtRA2 ko mice vs Wild-Type (Kristina Klupsch) E-GEOD-13034 HtrA2 ko MEFs fibroblast vs Wild-Type (Kristina Klupsch) E-GEOD-8030 MPTP-treated mice vs untreated (Mark Chin) E-GEOD-8030 METH-treated mice vs untreated (Mark Chin) E-GEOD-7707 Frontal area MPTP-treated mice vs untreated (Daniel Sforza) E-GEOD-7707 Midbrain area MPTP-treated mice vs untreated (Daniel Sforza) E-GEOD-7707 Striatum area MPTP-treated mice vs untreated (Daniel Sforza) E-GEOD-4758 Transgenic mice overexpressing alpha-synuclein vs Wild-Type (Elizabeth Salomon) E-GEOD-4758 Transgenic mice overexpressing HSP70 vs Wild-Type (Elizabeth Salomon) E-GEOD-4758 Transgenic mice overexpressing HSP70/alpha-synuclein vs Wild-Type (Elizabeth Salomon) E-GEOD-20547 Time course comparing TgA,TgB and wt at 6 18 28 days. (Michael Bonin) E-GEOD-16192 overexpression of alpha- and beta- Hb chains vs control (Paola Roncaglia) E-GEOD-13035 wt MEF rotenone vs wt MEF control (Kristina Klupsch) E-GEOD-13035 HtrA2_KO_rotenone vs HtrA2_KO_control (Kristina Klupsch) E-GEOD-13035 HtrA2 KO mouse cortex vs WT mouse cortex (Kristina Klupsch) E-MEXP-1383 Transgenic mouse alpha-synuclein +/- vs wild type -/- (Talene Yacoubian) -- RATTUS NORVEGICUS -- E-GEOD-15920 Neuronal primary coltures vs Mesencephalon Midbrain cells (Dario Greco) E-GEOD-1157 Substantia Nigra pars compacta tissue vs Ventral Tegmental Area (Eric Hoffman) E-GEOD-18055 Anterior Cingulate Cortex Cocaine Self administration TsA treatment vs Anterior Cingulate Cortex Cocaine Self administration (Doulaye Dembele) E-GEOD-18055 Nucleus Accubens Cocaine Self administration TsA treatment vs Nucleus Accubens Cocaine Self administration (Doulaye Dembele)

Select list two

-- DANIO RERIO -- E-GEOD-13348 Foggy mutant zebrafish vs Wild Type (Elizabeth Salomon) -- HOMO SAPIENS -- E-GEOD-7307 Substantia Nigra pars compacta cDNA from Parkinson's patients VS Substantia Nigra pars compacta cDNA from healthy patients (Richard Roth) E-GEOD-20141 Substantia Nigra pars compacta cDNA from Parkinson's patients VS Substantia Nigra pars compacta cDNA from healthy patients (Frank Middleton) E-MEXP-1416 Substantia Nigra pars compacta cDNA from Parkinson's patients VS Substantia Nigra pars compacta cDNA from healthy patients (Ippolita Cantuti-Castelvetri) E-GEOD-8397 Set 1. Lateral Substantia Nigra cDNA from Parkinson's patients VS Lateral Substantia Nigra cDNA from healthy patients (Linda Moran) E-GEOD-8397 Set 1. Medial Substantia Nigra cDNA from Parkinson's patients VS Medial Substantia Nigra cDNA from healthy patients (Linda Moran) E-GEOD-8397 Set 1. Superior (Frontal Cortex) cDNA from Parkinson's patients VS Superior Substantia Nigra cDNA from healthy patients (Linda Moran) E-GEOD-8397 Set 2. Lateral Substantia Nigra cDNA from Parkinson's patients VS Lateral Substantia Nigra cDNA from healthy patients (Linda Moran) E-GEOD-8397 Set 2. Medial Substantia Nigra cDNA from Parkinson's patients VS Medial Substantia Nigra cDNA from healthy patients (Linda Moran) E-GEOD-8397 Set 2. Superior (Frontal Cortex) cDNA from Parkinson's patients VS Superior Substantia Nigra cDNA from healthy patients (Linda Moran) E-GEOD-7621 Substantia Nigra cDNA from Parkinson's patients VS Substantia compacta cDNA from healthy patients (Jarlath ffrench-Mullen) E-GEOD-20146 Globus Pallidus cDNA from Parkinson's patients VS Globus Pallidus cDNA from healthy patients (Frank Middleton) E-GEOD-20153 B lymphocytes transformed with EBV cDNA from Parkinson's patients VS B lymphocytes transformed with EBV cDNA from healthy patients (Frank Middleton) E-GEOD-6613 Total blood cDNA from Parkinson's patients VS Total blood cDNA from healthy patients (Aron Eklund) E-GEOD-20168 Prefrontal cortex area 9 cDNA from Parkinson's patients VS Prefrontal cortex area 9 cDNA from healthy patients (Frank Middleton) E-GEOD-14429 Human HEK293 cells treated with proteasome inhibitor epoxomicin vs untreated cells (Allen HK Chang) E-GEOD-4773 Cultured SK-N-MC neuroblastoma cells at 1 week during rotenone exposure vs untreated (Elizabeth Salomon) E-GEOD-4773 Cultured SK-N-MC neuroblastoma cells at 2 week during rotenone exposure vs untreated (Elizabeth Salomon) E-GEOD-4773 Cultured SK-N-MC neuroblastoma cells at 3 week during rotenone exposure vs untreated (Elizabeth Salomon) E-GEOD-3064 X linked dystonia parkinsonism patients vs control tissue (Gen Tamiya) E-GEOD-20333 Substantia Nigra from Parkinso's patients vs control (jasmine jacob ) E-GEOD-20295 Parkinson's disease multiple brain regions vs control (Frank Middleton) E-GEOD-20291 Parkinson's disease putament vs control (Frank Middleton) E-GEOD-20292 Parkinson's disease substantia nigra vs control (Frank Middleton) E-GEOD-17204 Human neuroblastoma cells stably transfected with RNAi against DJ-1 vs scramble (Paola Roncaglia) -- MUS MUSCULUS -- E-GEOD-13033 HtRA2 ko mice vs Wild-Type (Kristina Klupsch) E-GEOD-13034 HtrA2 ko MEFs fibroblast vs Wild-Type (Kristina Klupsch) E-GEOD-8030 MPTP-treated mice vs untreated (Mark Chin) E-GEOD-8030 METH-treated mice vs untreated (Mark Chin) E-GEOD-7707 Frontal area MPTP-treated mice vs untreated (Daniel Sforza) E-GEOD-7707 Midbrain area MPTP-treated mice vs untreated (Daniel Sforza) E-GEOD-7707 Striatum area MPTP-treated mice vs untreated (Daniel Sforza) E-GEOD-4758 Transgenic mice overexpressing alpha-synuclein vs Wild-Type (Elizabeth Salomon) E-GEOD-4758 Transgenic mice overexpressing HSP70 vs Wild-Type (Elizabeth Salomon) E-GEOD-4758 Transgenic mice overexpressing HSP70/alpha-synuclein vs Wild-Type (Elizabeth Salomon) E-GEOD-20547 Time course comparing TgA,TgB and wt at 6 18 28 days. (Michael Bonin) E-GEOD-16192 overexpression of alpha- and beta- Hb chains vs control (Paola Roncaglia) E-GEOD-13035 wt MEF rotenone vs wt MEF control (Kristina Klupsch) E-GEOD-13035 HtrA2_KO_rotenone vs HtrA2_KO_control (Kristina Klupsch) E-GEOD-13035 HtrA2 KO mouse cortex vs WT mouse cortex (Kristina Klupsch) E-MEXP-1383 Transgenic mouse alpha-synuclein +/- vs wild type -/- (Talene Yacoubian) -- RATTUS NORVEGICUS -- E-GEOD-15920 Neuronal primary coltures vs Mesencephalon Midbrain cells (Dario Greco) E-GEOD-1157 Substantia Nigra pars compacta tissue vs Ventral Tegmental Area (Eric Hoffman) E-GEOD-18055 Anterior Cingulate Cortex Cocaine Self administration TsA treatment vs Anterior Cingulate Cortex Cocaine Self administration (Doulaye Dembele) E-GEOD-18055 Nucleus Accubens Cocaine Self administration TsA treatment vs Nucleus Accubens Cocaine Self administration (Doulaye Dembele)

Choose your filter.
PValue	(eg. <= 0.05)
Positive LogFC	(eg. >= 0.5)
Negative LogFC	(eg. <= -0.5)
Adj PValue	(eg. <= 0.05)

Contact: Cristian Taccioli, PhD